

# Chemicals

# Prices remain stable MoM

# **Summary**

Majority of the chemicals maintained a stable pricing trajectory on MoM basis in Dec-23. Crude pricing also stayed stable at \$79 on a monthly basis which aided pricing stability. We expect Chinese led dumping and pressure on inventory levels in the agrochemical space to begin gradually easing by Q4FY24 only. Pricing for most of the chemicals seem to have bottomed out on account of the intense dumping. Global demand continues to remain weak on account of various macroeconomic and geopolitical factors. Modest recovery is expected in FY25. Companies which are higher up the specialty chemicals value chain stand to benefit immensely from a longer term perspective. In light of the same, our top picks are SRF and Navin Fluorine on the back of their robust fluorination prowess and strong capex plans.

# **Key Highlights**

- Pricing Highlights: Heavy soda ash and caustic soda prices have registered sharp decline of 10% and 9% MoM which bodes negatively for major manufacturers such as Tata Chemicals/GHCL and Grasim/GACL respectively. Methanol price increased by 10% MoM benefitting prominent players such as RCF and NFL. Acetonitrile prices increased by a healthy 6% MoM benefitting major players such as Alkyl Amines and Balaji Amines. Acetone prices corrected by 14% MoM impacting major manufacturers such as Deepak Nitrite.
- Outlook: We believe that commodity chemicals segment could remain range bound from the current levels owing to decent domestic demand. However Chinese competition will continue to exert pricing pressure especially on commodity chemicals. We prefer specialty chemical players with decades of rich experience, strong R&D and execution capabilities. Companies that are delivering value added products and moving up the value chain will fare better as compared to pure commodity plays in the long term.

# Valuation snapshot

		Mkt Cap	СМР	TP	Upside	PE	R (x)
Companies	Reco	Rs bn	(Rs)	(Rs)	(%)	FY25E	FY26E
SRF	BUY	735	2481	2913	18	35	28
Navin Fluorine	BUY	191	3852	4625	20	41	32
Ami Organics	BUY	41	1122	1300	29	37	30
Clean Science	HOLD	165	1549	1425	(8)	50	36
Neogen Chem.	HOLD	39	1481	1700	15	53	43

Source: IDBI Capital Research

Jason Soans

jason.soans@idbicapital.com +91-22-2217 1727 Aayush Rathi

aayush.rathi@idbicapital.com +91-22-2217 1840



**Exhibit 1: Pricing Snapshot** 

Chemical	Dec-23	Dec-22	YoY (Chg)	Nov-23	MoM (Chg)	Peak Price	Drawdown from Peak	
Benzene	90	92	-2%	90	0%	120	-25%	
Aniline	158	190	-17%	155	2%	254	-38%	
Heavy Soda Ash	33	46	-28%	37	-10%	55	-40%	
Toluene	90	97	-7%	93	-3%	155	-42%	
Phthalic Anhydride	95	101	-6%	94	1%	134	-29%	
Monoethylene Glycol (MEG)	63	65	-3%	59	7%	91	-31%	
Phenol	100	127	-21%	104	-4%	166	-40%	
Acetone	89	66	35%	104	-14%	130	-32%	
Isopropyl Alcohol (IPA)	120	100	20%	120	0%	150	-20%	
Acetonitrile	133	165	-19%	125	6%	330	-60%	
Acetic Acid	62	57	9%	60	3%	160	-61%	
Caustic Soda Lye	31	60	-48%	34	-9%	72	-57%	
Ethyl Acetate	89	90	-1%	87	2%	140	-36%	
Toluene Diisocyanate (TDI)	200	245	-18%	199	1%	300	-33%	
Maleic Anhydride	94	90	4%	93	1%	174	-46%	
Methanol	34	34	0%	31	10%	54	-37%	
Acrylic Acid	81	162	-50%	77	5%	231	-65%	
Vinyl Acetate Monomer	84	114	-26%	92	-9%	290	-71%	
LDPE	100	123	-19%	107	-6%	151	-34%	
HDPE	89	113	-21%	107	-17%	138	-35%	

Source: Indianpetrochem, Change % based on month end prices, Peak Price =Max (From Jan-2021 to current date)



**Exhibit 2: Brief Profile** 

Chemicals	Indian Manufacturer	Major Consumer				
Benzene	BPCL, RIL, IOCL, ONGC	Aarti Inds, Apcotex, CFS, NFIL, Vinati, Deepak Nitrite, Valiant Org, Jyothy Labs				
Aniline	GNFC, HOCL	Aarti Ind, Atul Ltd, Aurobindo, Bayer, Monsanto, UPL, BASF, Deepak Nitrite, Nocil, Valiant Org, Bodal, Bhageria, Kiri				
Soda Ash	Tata Chem, GHCL, DCW, GFL	Deepak Nitrite				
Toluene	Reliance, BPCL, Indian Oil	Aarti, NFIL, Vinati, Deepak Nitrite				
Phthalic Anhydride	Thirumalai Chem, IGPL					
Mono Ethylene Glycol	RIL, India Glycols, IOCL					
Phenol	Deepak Phenolics, Hindustan Organics					
Acetone	Deepak Phenolics, SI Group	GSFC, ITC, Berger, Shalimar, Torrent Pharma, Sun Pharma, Asia Paints, Kansai Nerolac, Pfizer, NFIL				
Iso Propyl Alcohol (IPA)	Deepak Nitrite, Deepak Fertilisers & Petrochemicals					
Acetonitrile	Alkyl amines, Balaji amines, Deepak Novochem					
Acetic acid	GNFC	Reliance, IOCL, Apcotex, SRF, Deepak Nitrite, Laxmi Org.				
Caustic soda	Grasim, DCM Shriram, GACL, Nalco, RIL, DCW, TGV Sraac	Arvind Mills, Deepak Nitrite, GNFC, GSFC, IOC, Meghmani Organics, Nirma, NALCO, HUL, UPL				
Ethyl Acetate	GNFC, Jubilant Ingrevia, Laxmi Organics					
TDI	BASF, GNFC					
High-Density Polyethylene (HDPE)	Reliance, ONGC, GAIL					
Low-Density Polyethylene (LDPE)	Reliance					
Maleic Anhydride	Thirumalai Chem, IGPL					
Methanol	RCF, NFL, IOCL, Deepak Fertilizers, GNFC, GSFC	Alkyl Amines, Balaji Amines, Aarti, CFS, NFIL, SRF, Vinati				
PAN (Phthalic Anhydride)	Thirumalai Chem, IGPL					
Acrylic Acid	BPCL, IOCL, BASF, GSFC	Apcotex, Black Rose, Balmer Lawrie, Fineotex				

Source: Company; IDBI Capital Research










Exhibit 4: Aniline Prices up by ~2% MoM



Source: Indianpetrochem

Source: Indianpetrochem

# Exhibit 5: Heavy Soda Ash down by ~10% MoM




Source: Indianpetrochem

Exhibit 6: Toluene Prices down by ~3% MoM











Source: Indianpetrochem

Exhibit 8: Monoethylene Glycol up by ~7% MoM




Source: Indianpetrochem

Exhibit 9: Phenol Prices down by ~4% MoM



Source: Indianpetrochem

Exhibit 10: Acetone Prices down by ~14% MoM












Exhibit 12: Acetonitrile Prices up by ~6% MoM



Source: Indianpetrochem

Source: Indianpetrochem

Exhibit 13: Acetic Acid Prices up by ~3% MoM




Source: Indianpetrochem

Exhibit 14: Caustic Soda Prices down by ~9% MoM









## Exhibit 16: Toluene Diisocyanate up by ~1% MoM



Source: Indianpetrochem


Source: Indianpetrochem

# Exhibit 17: Maleic Anhydride up by ~1% MoM




Source: Indianpetrochem


Exhibit 18: HDPE down by ~17% MoM





Aug-23 Sep-23 Oct-23 Nov-23







**Exhibit 23: Sectoral Stock Performance** 

	Mkt Cap	Performance (%)					Relative to Index (%)				
	Rs bn	1M	12M	3 Year	5 Year	1M	12M	3 Year	5 Year		
SRF	735	5	9	118	519	-3	-11	63	419		
Gujarat Fluorochemicals	406	27	17	540	-	19	-2	485	-		
Deepak Nitrite	338	13	26	151	1,044	4	6	96	944		
Aarti Industries	235	16	6	18	112	8	-13	-37	12		
Navin Fluorine International	191	4	-5	46	455	-4	-25	-9	355		
Clean Science	165	15	5	-	-	7	-15	-	-		
Fine Organics	153	18	-12	97	323	10	-31	42	223		
Alkyl Amines	130	19	-4	63	742	11	-24	8	642		
Aether Industries	118	7	6	-	-	-1	-14	-	-		
GNFC	117	9	37	234	120	1	17	179	20		
Anupam Rasayan	113	9	58	-	-	1	39	-	-		
Galaxy Surfactants	98	-1	12	38	130	-9	-7	-17	30		
Balaji Amines	86	32	-1	184	492	24	-21	129	392		
Jubilant Ingrevia	81	19	-4	-	-	11	-24	-	-		
Laxmi Organics	80	9	-1	-	-	1	-20	-	-		
Gujarat Alkalies and Chemicals	57	7	5	122	42	-1	-14	67	-58		
GHCL	56	7	17	181	149	-1	-2	126	49		
Ami Organics	41	1	17	-	-	-8	-2	-	-		
Neogen Chemicals	39	-2	20	101	-	-10	0	46	-		
I G Petrochemicals	14	5	-9	11	12	-3	-29	-44	-88		

Source: Bloomberg, IDBI Capital Research





Dealing (91-22) 6836 1111 dealing@idbicapital.com

**Key to Ratings Stocks:** 

**BUY:** 15%+; **HOLD:** -5% to 15%; **SELL:** -5% and below.

IDBI Capital Markets & Securities Ltd.

**Equity Research Desk** 

6th Floor, IDBI Tower, WTC Complex, Cuffe Parade, Colaba, Mumbai – 400 005. Phones: (91-22) 2217 1700; Fax: (91-22) 2215 1787; Email: info@idbicapital.com

SEBI Registration: BSE & NSE (Cash & FO) - INZ000007237, NSDL - IN-DP-NSDL-12-96, Research - INH000002459, CIN - U65990MH1993GOI075578

Compliance Officer: Mr. Pushkar Vartak; Email: compliance@idbicapital.com; Telephone: (91-22) 2217 1907

#### Disclaimer

This report has been published by IDBI Capital Markets & Securities Ltd.(hereinafter referred to as "IDBI Capital") for private circulation. This report should not be reproduced or copied or made available to others. No person associated with IDBI Capital is obligated to call or initiate contact with you for the purposes of elaborating or following up on the information contained in this report. The information contained herein is strictly confidential and meant for solely for the selected recipient and may not be altered in any way, transmitted to copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without the prior written consent of IDBI Capital.

Recipients may not receive this report at the same time as other recipients. IDBI Capital will not treat recipients as customers by virtue of their receiving this report.

The information contained herein is from the public domain or sources believed to be reliable, but we do not make any representation or warranty that it is accurate, complete or up-to-date and it should not be reliable upon as such. While reasonable care has been taken to ensure that information given is at the time believed to be fair and correct and opinions based thereupon are reasonable, due to the very nature of research it cannot be warranted or represented that it is accurate or complete and it should not be reliable upon as such. In so far as this report includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Opinions expressed are current opinions as of the date appearing on this material only. While we endeavor to update on a reasonable basis, the information discussed in this material, IDBI Capital, its directors, employees are under no obligation to update or keep the information current. Further there may be regulatory, compliance, or other reasons that prevent us from doing so.

Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice.

IDBI Capital, its directors and employees and any person connected with it, will not in any way be responsible for the contents of this report or for any losses, costs, expenses, charges, including notional losses/lost opportunities incurred by a recipient as a result of acting or non-acting on any information/material contained in the report.

This is not an offer to sell or a solicitation to buy any securities or an attempt to influence the opinion or behavior of investors or recipients or provide any investment/tax advice.

This report is for information only and has not been prepared based on specific investment objectives. The securities discussed in this report may not be suitable for all investors. Investors must make their own investment decision based on their own investment objectives, goals and financial position and based on their own analysis.

Trading in stocks, stock derivatives, and other securities is inherently risky and the recipient agrees to assume complete and full responsibility for the outcomes of all trading decisions that the recipient makes, including but not limited to loss of capital.

Opinions, projections and estimates in this report solely constitute the current judgment of the author of this report as of the date of this report and do not in any way reflect the views of IDBI Capital, its directors, officers, or employees.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject IDBI Capital and associates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this report may come are required to inform themselves of and to observe such restriction.

E-mail is not a secure method of communication. IDBI Capital cannot accept responsibility for the accuracy or completeness of any e-mail message or any attachment(s).

This transmission could contain viruses, be corrupted, destroyed, incomplete, intercepted, lost or arrived late. IDBI Capital, its directors or employees or associates accept no liability for any damage caused, directly or indirectly, by this email.

## Chemicals | Monthly Pricing Update



### **Analyst Disclosures**

We, Jason Soans and Aayush Rathi, hereby certify that the views expressed in this report accurately reflect my personal views about the subject companies and / or securities. We also certify that no part of our compensation were, are or would be directly or indirectly related to the specific recommendations or views expressed in this report. Principally, we will be responsible for the preparation of this research report and have taken reasonable care to achieve and maintain independence and objectivity in making any recommendations herein.

#### Other Disclosure

IDBI Capital Markets & Securities Ltd. (herein after referred to as "IDBI Capital") was incorporated in the year 1993 under Companies Act, 1956 and is a wholly owned subsidiary of IDBI Bank Limited. IDBI Capital is one of India's leading securities firm which offers a full suite of products and services to individual, institutional and corporate clients namely Stock broking (Institutional and Retail), Distribution of financial products, Merchant Banking, Corporate Advisory Services, Debt Arranging & Underwriting, Portfolio Manager Services and providing Depository Services. IDBI Capital is a registered trading and clearing member of BSE Ltd. (BSE) and National Stock Exchange of India Limited (NSE). IDBI Capital is also a SEBI registered Merchant Banker, Portfolio Manager and Research Analyst. IDBI Capital is also a SEBI registered depository participant with National Securities Depository Limited (NSDL) and is also a Mutual Fund Advisor registered with Association of Mutual Funds in India (AMFI).

IDBI Capital and its associates IDBI Bank Ltd. (Holding Company), IDBI Intech Ltd. (Fellow Subsidiary), IDBI Asset Management Ltd. (Fellow Subsidiary) and IDBI Trusteeship Services Ltd. (Fellow Subsidiary).

IDBI Group is a full-serviced banking, integrated investment banking, investment management, brokerage and financing group. Details in respect of which are available on www.idbicapital.com IDBI Capital along with its associates are leading underwriter of securities and participants in virtually all securities trading markets in India. We and our associates have investment banking and other business relationships with a significant percentage of the companies covered by our Research Department. Investors should assume that IDBI Capital and/or its associates are seeking or will seek investment banking or other business from the company or companies that are the subject of this material. IDBI Capital generally prohibits its analysts, persons reporting to analysts, and their dependent family members having a financial conflict of interest in the securities or derivatives of any companies that the analysts cover. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Directors of IDBI Capital are the subject of this material is provided herein. This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of clients of IDBI Capital. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material

IDBI Capital hereby declares that our activities were neither suspended nor we have materially defaulted with any Stock Exchange authority with whom we are registered in last five years. However SEBI, Exchanges and Depositories have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on IDBI Capital for certain operational deviations. We have not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has our certificate of registration been cancelled by SEBI at any point of time. IDBI Capital, its directors or employees or associates, may from time to time, have positions in, or options on, and buy and sell securities referred to herein. IDBI Capital or its associates go or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or their affiliate companies or act as advisor or lender / borrower to such company(ies)/associates companies or have other potential conflict of interest. This report may provide hyperlinks to other websites. Except to the extent to which the report refers to the website of IDBI Capital, IDBI Capital states that it has not reviewed the linked site and takes no responsibility for the content contained in such other websites. Accessing such websites shall be at recipient's own risk. IDBI Capital encourages the practice of giving independent opinion in research report preparation by the analyst and thus strives to minimize the conflict in preparation of research report. Accordingly, neither IDBI Capital nor Research Analysts have any material conflict of interest at the time of publication of this report. We offer our research services to primarily institutional investors and their employees, directors, fund managers, advisors who are registered with us. The Research Analyst has not served as an officer, director or employee of Subject Company. We or our associates may have received compensation for investment banking or merchant banki